中国组织工程研究
中國組織工程研究
중국조직공정연구
Journal of Clinical Rehabilitative Tissue Engineering Research
2014年
46期
7528-7532
,共5页
于清波%邓剑锋%高大新%宋红%严佳亮%齐曦明%王东兴
于清波%鄧劍鋒%高大新%宋紅%嚴佳亮%齊晞明%王東興
우청파%산검봉%고대신%송홍%엄가량%제희명%왕동흥
组织构建%组织工程%玻璃酸钠%膝骨关节炎%丙二醛%超氧化物歧化酶%关节液
組織構建%組織工程%玻璃痠鈉%膝骨關節炎%丙二醛%超氧化物歧化酶%關節液
조직구건%조직공정%파리산납%슬골관절염%병이철%초양화물기화매%관절액
malondialdehyde%superoxide dismutase%osteoarthritis,knee%synovial fluid
背景:玻璃酸钠关节腔注射是治疗膝骨关节炎的一种有效方法,疗效显著,不良反应少,但其作用机制尚不明确。目的:通过检测玻璃酸钠注射前后膝骨关节炎关节液中丙二醛、超氧化物歧化酶水平,评价玻璃酸钠治疗膝骨关节炎的具体机制。方法:纳入膝骨关节炎患者37例(40膝),根据日本膝骨关节炎指征等级分轻度组10例10膝、中度组17例18膝、重度组10例12膝,患膝关节注入玻璃酸钠25 mg,每周注射1次,连续5次为1个疗程。注射前及注射4周后检测关节液丙二醛、超氧化物歧化酶水平,以及按照日本膝骨关节炎指征等级对所有患者治疗前后行临床评分。结果与结论:轻度组、中度组注射4周后临床评分较注射前显著降低(P<0.05),重度组注射前后临床评分比较差异无显著性意义。3组注射4周后关节液丙二醛水平均较注射前显著下降(P <0.05),关节液超氧化物歧化酶水平均较注射前显著升高(P <0.05)。结果表明玻璃酸钠可通过降低关节液中丙二醛水平、升高超氧化物歧化酶水平治疗膝骨关节炎,并且更适用于轻、中度患者。
揹景:玻璃痠鈉關節腔註射是治療膝骨關節炎的一種有效方法,療效顯著,不良反應少,但其作用機製尚不明確。目的:通過檢測玻璃痠鈉註射前後膝骨關節炎關節液中丙二醛、超氧化物歧化酶水平,評價玻璃痠鈉治療膝骨關節炎的具體機製。方法:納入膝骨關節炎患者37例(40膝),根據日本膝骨關節炎指徵等級分輕度組10例10膝、中度組17例18膝、重度組10例12膝,患膝關節註入玻璃痠鈉25 mg,每週註射1次,連續5次為1箇療程。註射前及註射4週後檢測關節液丙二醛、超氧化物歧化酶水平,以及按照日本膝骨關節炎指徵等級對所有患者治療前後行臨床評分。結果與結論:輕度組、中度組註射4週後臨床評分較註射前顯著降低(P<0.05),重度組註射前後臨床評分比較差異無顯著性意義。3組註射4週後關節液丙二醛水平均較註射前顯著下降(P <0.05),關節液超氧化物歧化酶水平均較註射前顯著升高(P <0.05)。結果錶明玻璃痠鈉可通過降低關節液中丙二醛水平、升高超氧化物歧化酶水平治療膝骨關節炎,併且更適用于輕、中度患者。
배경:파리산납관절강주사시치료슬골관절염적일충유효방법,료효현저,불량반응소,단기작용궤제상불명학。목적:통과검측파리산납주사전후슬골관절염관절액중병이철、초양화물기화매수평,평개파리산납치료슬골관절염적구체궤제。방법:납입슬골관절염환자37례(40슬),근거일본슬골관절염지정등급분경도조10례10슬、중도조17례18슬、중도조10례12슬,환슬관절주입파리산납25 mg,매주주사1차,련속5차위1개료정。주사전급주사4주후검측관절액병이철、초양화물기화매수평,이급안조일본슬골관절염지정등급대소유환자치료전후행림상평분。결과여결론:경도조、중도조주사4주후림상평분교주사전현저강저(P<0.05),중도조주사전후림상평분비교차이무현저성의의。3조주사4주후관절액병이철수평균교주사전현저하강(P <0.05),관절액초양화물기화매수평균교주사전현저승고(P <0.05)。결과표명파리산납가통과강저관절액중병이철수평、승고초양화물기화매수평치료슬골관절염,병차경괄용우경、중도환자。
BACKGROUND:Intra-articular injection of sodium hyaluronate is an effective method for the treatment of knee osteoarthritis, with significant effect and less adverse reactions, but the mechanism is unclear. OBJECTIVE:Through testing the malondialdehyde and superoxide dismutase levels in the synovial fluid of knee osteoarthritis before and after injection of sodium hyaluronate, to evaluate the clinical efficacy of sodium hyaluronate in the treatment of knee osteoarthritis. METHODS:Thirty-seven patients with knee osteoarthritis (40 knees) were enroled and divided into mild (n=10, 10 knees), moderate (n=17, 18 knees), and severe (n=10, 12 knees) groups according to the Japan's knee osteoarthritis indications. Patients were subjected to intra-articular injection of 25 mg sodium hyaluronate, once a week for 5 weeks. The levels of malondialdehyde and superoxide dismutase in the synovial fluid before and 4 weeks after treatment were detected, and then clinical effects were evaluated based on the clinical scores according to the Japan’s knee osteoarthritis indications. RESULTS AND CONCLUSION: The indication rating results of the mild and moderate groups were decreased significantly 4 weeks after injection (P < 0.05), but there were no significant difference in the severe group before and after treatment. The malondialdehyde level in the synovial fluid was decreased obviously in the three groups at 4 weeks after injection (P < 0.05), while the level of superoxide dismutase was increased remarkably (P < 0.05). These findings indicate that sodium hyaluronate can treat knee osteoarthritis by reducing the malondialdehyde level and increasing superoxide dismutase level in the synovial fluid, but this method is more suitable for treatment of mild to moderate knee osteoarthritis.